<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01227421</url>
  </required_header>
  <id_info>
    <org_study_id>RM08-3001</org_study_id>
    <nct_id>NCT01227421</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo Controlled Study of Nitazoxanide in Adults and Adolescents With Acute Uncomplicated Influenza</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Romark Laboratories L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Romark Laboratories L.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized clinical trial designed to evaluate the safety/efficacy of two dosing
      regimens of oral nitazoxanide compared to placebo in the treatment of acute uncomplicated
      influenza in adults and adolescents. The investigators hypothesize that treatment with
      Nitazoxanide will reduce the duration of symptoms in patients with confirmed influenza
      infection. Secondarily, the investigators hypothesize that treatment with nitazoxanide will
      reduce the complications of influenza, severity of symptoms, time lost from work, time to
      return to normal daily activities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Double-Blind, Placebo Controlled Study of Nitazoxanide in Adults and
      Adolescents with Acute Uncomplicated Influenza. The primary objectives of this study are to
      demonstrate the efficacy of nitazoxanide administered 300 mg two times per day for 5 days or
      600 mg two times per day for 5 days in reducing the time to resolution of all clinical
      symptoms of influenza.

      The study will also evaluate pharmacokinetics of nitazoxanide in a subset of 24 patients and
      the safety of the nitazoxanide regimen compared to a placebo via analysis of adverse events
      and laboratory safety tests.

      Blood samples will be collected for all patients at baseline, day 7 and day 28, and for a
      subset of 24 patients aged 18-65 years (pharmacokinetics subset) on day 2. Urine samples will
      be collected at baseline and day 7. Nasal swabs will be collected at baseline and day 7 for
      all patients and on days 2, 3, 4 and 5 for a subset of patients (approximately 20% of
      patients).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Resolution of All Clinical Symptoms of Influenza as Reported by the Subjects</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>The primary efficacy analysis for this study was to demonstrate the efficacy of Nitazoxanide (NTZ) administered as 300 mg b.i.d. for 5 days or 600 mg b.i.d. for 5 days in reducing the time to resolution of all clinical symptoms of influenza in patients with laboratory confirmed influenza infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Each Individual Symptom of Influenza as Reported by the Subjects</measure>
    <time_frame>at least 28 days</time_frame>
    <description>Time in hours (Median and Interquartile range)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change (Standard Deviation)in 50% Tissue Culture Infective Dose (TCID50) Viral Titer From Baseline</measure>
    <time_frame>7 days</time_frame>
    <description>Change in viral titer presented as logarithm with base 10 (log10) 50% Tissue Culture Infective Dose (TCID50)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in RT-PCR (Reverse Transcription Polymerase Chain Reaction) Viral Titer From Baseline</measure>
    <time_frame>7 days</time_frame>
    <description>Change in viral titer logarithm with base 10 (log10) Ribonucleic Acid (RNA)copies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cessation of Viral Shedding Measure by 50% Tissue Culture Infective Dose (TCID50)</measure>
    <time_frame>28 days</time_frame>
    <description>Median time in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Return to Normal Daily Activities</measure>
    <time_frame>28 days</time_frame>
    <description>Time in hours as reported by patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Severity Score Hours</measure>
    <time_frame>28 days</time_frame>
    <description>Sum of the symptom severity score hours from first dose to resolution of symptoms. Patients rated each symptom's severity on a score from 0 to 3 (0=absent, 1=mild, 2=moderate, 3=severe). Total symptom severity score hours were calculated by multiplying the sum of the severity scores by duration of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Loss From Work</measure>
    <time_frame>28 days</time_frame>
    <description>Time loss from work</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of Influenza</measure>
    <time_frame>28 days</time_frame>
    <description>Proportion of patients with a complication of influenza during the course of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influenza Antibody Response Titer Change: Influenza A 2009 H1N1</measure>
    <time_frame>28 days</time_frame>
    <description>change in influenza antibody titer for Influenza A 2009 H1N1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influenza Antibody Response: Influenza A H3N2</measure>
    <time_frame>28 days</time_frame>
    <description>Change in antibody titer for Influenza A H3N2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influenza Antibody Response: Influenza B</measure>
    <time_frame>28 days</time_frame>
    <description>Change in antibody titer for Influenza B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influenza Antibody Response: Seroprotection and Seroconversion for Patients With Influenza A 2009 H1N1</measure>
    <time_frame>28 days</time_frame>
    <description>Proportion of patients seroprotected or seroconverted at day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influenza Antibody Response: Seroprotection and Seroconversion for Patients With Influenza A H3N2</measure>
    <time_frame>28 days</time_frame>
    <description>Proportion of patients seroprotected and seroconverted at day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influenza Antibody Response: Seroprotection and Seroconversion for Influenza B</measure>
    <time_frame>28 days</time_frame>
    <description>Proportion of patients seroprotected and seroconverted at day 28</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">624</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Nitazoxanide, Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300 mg nitazoxanide tablet and 1 placebo tablet twice daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitazoxanide, Nitazoxanide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two 300 mg nitazoxanide tablets(600mg) twice daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 placebo tablets twice daily for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
    <description>Tablets, 300 mg (one 300 mg tablet + 1 placebo tablet) with food twice daily for 5 days</description>
    <arm_group_label>Nitazoxanide, Placebo</arm_group_label>
    <other_name>Alinia, NTZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
    <description>Tablets, 600 mg (two 300 mg tablets) with food twice daily for 5 days</description>
    <arm_group_label>Nitazoxanide, Nitazoxanide</arm_group_label>
    <other_name>Alinia, NTZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, (2 tablets) twice daily with food for 5 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          -  age 12 to 65 years

          -  Presence of clinical signs, respiratory symptoms and constitutional symptoms
             compatible with influenza infection:

               1. fever,

               2. at least one of the following respiratory symptoms: cough, sore throat, nasal
                  discharge, nasal congestion, sneezing.

               3. At least one of the following constitutional symptoms: headache, myalgia, seats,
                  chills, fatigue of any severity (mild, moderate, severe)

          -  Confirmation of Influenza A or B infection in the local community

          -  Onset of illness no more than 48 hours before presentation. Time of onset of illness
             is defined as either the earlier of (1) the time when the temperature was first
             measured as elevated, or (2) the time when the patient experienced the presence of at
             least one respiratory symptom AND the presence of at least one constitutional symptom.

          -  willing and able to comply with protocol requirements and provide informed consent

        EXCLUSION CRITERIA:

          -  severity of illness requiring or anticipated to require in-hospital care

          -  High risk of complications from influenza as follows:

               1. persons with asthma or other chronic pulmonary diseases

               2. persons with hemodynamically significant cardiac disease

               3. persons who have immunosuppressive disorders or receiving immunosuppressive
                  therapy

               4. persons infected with Human Immunodeficiency Virus (HIV)

               5. persons with sickle cell anemia or other hemoglobinopathies

               6. persons with diseases requiring long-term aspirin therapy

               7. persons with chronic renal dysfunction

               8. persons with liver disorders

               9. Persons with cancer

              10. Persons with chronic metabolic disease such as diabetes and inherited
                  mitochondrial disorders

              11. Persons with neuromuscular disorders, seizure disorders, or cognitive dysfunction

              12. Residents of any age of nursing homes or long-term institutions.

          -  Females of child bearing age who are pregnant, breastfeeding or sexually active
             without birth control

          -  vaccination for influenza or H1N1 (Swine Flu) on or after August 1, 2010

          -  treatment with antiviral medication such as oseltamivir, zanamivir, amantadine, or
             rimantadine within 30 days of screening.

          -  Prior treatment with nitazoxanide within 30 days prior to screening.

          -  subjects with active respiratory allergies or expected to require anti-allergy
             medications during the study period.

          -  known sensitivity to nitazoxanide

          -  subjects unable to take oral medication

          -  subjects with chronic kidney or liver disease

          -  Presence of any other pre-existing chronic infection that is undergoing or requiring
             medical therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Francois Rossignol, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Romark Laboratories L.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Health Sciences Research Center</name>
      <address>
        <city>Elmira</city>
        <state>New York</state>
        <zip>14901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2010</study_first_submitted>
  <study_first_submitted_qc>October 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2010</study_first_posted>
  <results_first_submitted>May 30, 2012</results_first_submitted>
  <results_first_submitted_qc>November 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 8, 2014</results_first_posted>
  <last_update_submitted>January 8, 2014</last_update_submitted>
  <last_update_submitted_qc>January 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitazoxanide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nitazoxanide</title>
          <description>300 mg nitazoxanide twice daily with food for 5 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo tablet twice daily with food for 5 days</description>
        </group>
        <group group_id="P3">
          <title>Nitazoxanide</title>
          <description>2X 300 mg controlled release tablet twice daily with food for five days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
                <participants group_id="P2" count="212"/>
                <participants group_id="P3" count="211"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="190"/>
                <participants group_id="P2" count="194"/>
                <participants group_id="P3" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized in error</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nitazoxanide</title>
          <description>300 mg nitazoxanide twice daily with food for 5 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo tablet twice daily with food for 5 days</description>
        </group>
        <group group_id="B3">
          <title>Nitazoxanide</title>
          <description>2X 300 mg controlled release tablet twice daily with food for five days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="201"/>
            <count group_id="B2" value="212"/>
            <count group_id="B3" value="211"/>
            <count group_id="B4" value="624"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="188"/>
                    <measurement group_id="B4" value="553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" spread="12.6"/>
                    <measurement group_id="B2" value="31" spread="13.3"/>
                    <measurement group_id="B3" value="32" spread="13.2"/>
                    <measurement group_id="B4" value="31" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="212"/>
                    <measurement group_id="B3" value="211"/>
                    <measurement group_id="B4" value="624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Resolution of All Clinical Symptoms of Influenza as Reported by the Subjects</title>
        <description>The primary efficacy analysis for this study was to demonstrate the efficacy of Nitazoxanide (NTZ) administered as 300 mg b.i.d. for 5 days or 600 mg b.i.d. for 5 days in reducing the time to resolution of all clinical symptoms of influenza in patients with laboratory confirmed influenza infection</description>
        <time_frame>Up to 28 days</time_frame>
        <population>624 patients were enrolled based on inclusion/exclusion criteria. The primary efficacy analysis was conducted on the 257 patients with laboratory confirmed influenza.</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>300 mg nitazoxanide twice daily with food for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo tablet twice daily with food for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Nitazoxanide</title>
            <description>2X 300 mg controlled release tablet twice daily with food for five days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of All Clinical Symptoms of Influenza as Reported by the Subjects</title>
          <description>The primary efficacy analysis for this study was to demonstrate the efficacy of Nitazoxanide (NTZ) administered as 300 mg b.i.d. for 5 days or 600 mg b.i.d. for 5 days in reducing the time to resolution of all clinical symptoms of influenza in patients with laboratory confirmed influenza infection</description>
          <population>624 patients were enrolled based on inclusion/exclusion criteria. The primary efficacy analysis was conducted on the 257 patients with laboratory confirmed influenza.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.1" lower_limit="81.5" upper_limit="151.9"/>
                    <measurement group_id="O2" value="116.7" lower_limit="91.3" upper_limit="144.0"/>
                    <measurement group_id="O3" value="95.5" lower_limit="71.2" upper_limit="125.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of Each Individual Symptom of Influenza as Reported by the Subjects</title>
        <description>Time in hours (Median and Interquartile range)</description>
        <time_frame>at least 28 days</time_frame>
        <population>624 patients were enrolled based on inclusion/exclusion criteria. Secondary efficacy analyses were conducted on the 257 patients with laboratory confirmed influenza.</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>300 mg nitazoxanide twice daily with food for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo tablet twice daily with food for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Nitazoxanide</title>
            <description>2X 300 mg controlled release tablet twice daily with food for five days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Each Individual Symptom of Influenza as Reported by the Subjects</title>
          <description>Time in hours (Median and Interquartile range)</description>
          <population>624 patients were enrolled based on inclusion/exclusion criteria. Secondary efficacy analyses were conducted on the 257 patients with laboratory confirmed influenza.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="72" upper_limit="92"/>
                    <measurement group_id="O2" value="81" lower_limit="67" upper_limit="92"/>
                    <measurement group_id="O3" value="60" lower_limit="48" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="37" upper_limit="82"/>
                    <measurement group_id="O2" value="42" lower_limit="36" upper_limit="56"/>
                    <measurement group_id="O3" value="43" lower_limit="36" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore Throat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="48" upper_limit="74"/>
                    <measurement group_id="O2" value="52" lower_limit="36" upper_limit="72"/>
                    <measurement group_id="O3" value="50" lower_limit="31" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="75" upper_limit="117"/>
                    <measurement group_id="O2" value="104" lower_limit="84" upper_limit="111"/>
                    <measurement group_id="O3" value="84" lower_limit="60" upper_limit="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="36" upper_limit="60"/>
                    <measurement group_id="O2" value="48" lower_limit="39" upper_limit="60"/>
                    <measurement group_id="O3" value="39" lower_limit="30" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="36" upper_limit="52"/>
                    <measurement group_id="O2" value="46" lower_limit="39" upper_limit="57"/>
                    <measurement group_id="O3" value="42" lower_limit="30" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="52" upper_limit="83"/>
                    <measurement group_id="O2" value="69" lower_limit="60" upper_limit="72"/>
                    <measurement group_id="O3" value="60" lower_limit="38" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweats / Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="34" upper_limit="42"/>
                    <measurement group_id="O2" value="36" lower_limit="27" upper_limit="42"/>
                    <measurement group_id="O3" value="36" lower_limit="26" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="28" upper_limit="41"/>
                    <measurement group_id="O2" value="31" lower_limit="24" upper_limit="41"/>
                    <measurement group_id="O3" value="36" lower_limit="24" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change (Standard Deviation)in 50% Tissue Culture Infective Dose (TCID50) Viral Titer From Baseline</title>
        <description>Change in viral titer presented as logarithm with base 10 (log10) 50% Tissue Culture Infective Dose (TCID50)</description>
        <time_frame>7 days</time_frame>
        <population>Analysis conducted on 113 patients from intensive virologic follow up group with laboratory confirmed influenza</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>300 mg nitazoxanide twice daily with food for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo tablet twice daily with food for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Nitazoxanide</title>
            <description>2X 300 mg controlled release tablet twice daily with food for five days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change (Standard Deviation)in 50% Tissue Culture Infective Dose (TCID50) Viral Titer From Baseline</title>
          <description>Change in viral titer presented as logarithm with base 10 (log10) 50% Tissue Culture Infective Dose (TCID50)</description>
          <population>Analysis conducted on 113 patients from intensive virologic follow up group with laboratory confirmed influenza</population>
          <units>LOG10 Titer</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="1.4"/>
                    <measurement group_id="O2" value="-0.03" spread="1.7"/>
                    <measurement group_id="O3" value="-1.11" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.26" spread="1.8"/>
                    <measurement group_id="O2" value="-1.21" spread="2.2"/>
                    <measurement group_id="O3" value="-1.84" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" spread="1.9"/>
                    <measurement group_id="O2" value="-1.65" spread="1.9"/>
                    <measurement group_id="O3" value="-2.58" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.46" spread="1.8"/>
                    <measurement group_id="O2" value="-2.41" spread="1.8"/>
                    <measurement group_id="O3" value="-2.55" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.82" spread="1.6"/>
                    <measurement group_id="O2" value="-2.79" spread="1.8"/>
                    <measurement group_id="O3" value="-3.01" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in RT-PCR (Reverse Transcription Polymerase Chain Reaction) Viral Titer From Baseline</title>
        <description>Change in viral titer logarithm with base 10 (log10) Ribonucleic Acid (RNA)copies</description>
        <time_frame>7 days</time_frame>
        <population>Analysis conducted on 113 patients from the intensive virologic follow up group with laboratory confirmed influenza</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>300 mg nitazoxanide twice daily with food for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo tablet twice daily with food for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Nitazoxanide</title>
            <description>2X 300 mg controlled release tablet twice daily with food for five days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in RT-PCR (Reverse Transcription Polymerase Chain Reaction) Viral Titer From Baseline</title>
          <description>Change in viral titer logarithm with base 10 (log10) Ribonucleic Acid (RNA)copies</description>
          <population>Analysis conducted on 113 patients from the intensive virologic follow up group with laboratory confirmed influenza</population>
          <units>LOG10 RNA copies</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="1.4"/>
                    <measurement group_id="O2" value="-0.22" spread="1.7"/>
                    <measurement group_id="O3" value="-0.73" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="1.4"/>
                    <measurement group_id="O2" value="-0.92" spread="2.0"/>
                    <measurement group_id="O3" value="-1.64" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.75" spread="1.5"/>
                    <measurement group_id="O2" value="-1.63" spread="1.8"/>
                    <measurement group_id="O3" value="-2.21" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.42" spread="1.5"/>
                    <measurement group_id="O2" value="-2.49" spread="1.7"/>
                    <measurement group_id="O3" value="-2.44" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.97" spread="1.3"/>
                    <measurement group_id="O2" value="-2.82" spread="1.6"/>
                    <measurement group_id="O3" value="-3.08" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cessation of Viral Shedding Measure by 50% Tissue Culture Infective Dose (TCID50)</title>
        <description>Median time in hours</description>
        <time_frame>28 days</time_frame>
        <population>Analysis performed on 107 patients from the intensive virologic follow up population with laboratory confirmed influenza</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>300 mg nitazoxanide twice daily with food for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo tablet twice daily with food for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Nitazoxanide</title>
            <description>2X 300 mg controlled release tablet twice daily with food for five days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cessation of Viral Shedding Measure by 50% Tissue Culture Infective Dose (TCID50)</title>
          <description>Median time in hours</description>
          <population>Analysis performed on 107 patients from the intensive virologic follow up population with laboratory confirmed influenza</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.0" lower_limit="46" upper_limit="141"/>
                    <measurement group_id="O2" value="91.3" lower_limit="48" upper_limit="143"/>
                    <measurement group_id="O3" value="71.8" lower_limit="38" upper_limit="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Return to Normal Daily Activities</title>
        <description>Time in hours as reported by patient</description>
        <time_frame>28 days</time_frame>
        <population>Analysis conducted on 257 patients with laboratory confirmed influenza</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>300 mg nitazoxanide twice daily with food for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo tablet twice daily with food for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Nitazoxanide</title>
            <description>2X 300 mg controlled release tablet twice daily with food for five days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Return to Normal Daily Activities</title>
          <description>Time in hours as reported by patient</description>
          <population>Analysis conducted on 257 patients with laboratory confirmed influenza</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2" lower_limit="49" upper_limit="117"/>
                    <measurement group_id="O2" value="82.1" lower_limit="59" upper_limit="115"/>
                    <measurement group_id="O3" value="84.0" lower_limit="60" upper_limit="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Severity Score Hours</title>
        <description>Sum of the symptom severity score hours from first dose to resolution of symptoms. Patients rated each symptom's severity on a score from 0 to 3 (0=absent, 1=mild, 2=moderate, 3=severe). Total symptom severity score hours were calculated by multiplying the sum of the severity scores by duration of symptoms.</description>
        <time_frame>28 days</time_frame>
        <population>Analysis conducted for 257 patients with laboratory confirmed influenza</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>300 mg nitazoxanide twice daily with food for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo tablet twice daily with food for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Nitazoxanide</title>
            <description>2X 300 mg controlled release tablet twice daily with food for five days</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Severity Score Hours</title>
          <description>Sum of the symptom severity score hours from first dose to resolution of symptoms. Patients rated each symptom's severity on a score from 0 to 3 (0=absent, 1=mild, 2=moderate, 3=severe). Total symptom severity score hours were calculated by multiplying the sum of the severity scores by duration of symptoms.</description>
          <population>Analysis conducted for 257 patients with laboratory confirmed influenza</population>
          <units>symptom score *hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1035.1" spread="765"/>
                    <measurement group_id="O2" value="1220.9" spread="592"/>
                    <measurement group_id="O3" value="1125.2" spread="681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Loss From Work</title>
        <description>Time loss from work</description>
        <time_frame>28 days</time_frame>
        <population>Analysis conducted on 241 patients with laboratory confirmed influenza excluding those who are unemployed</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>300 mg nitazoxanide twice daily with food for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo tablet twice daily with food for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Nitazoxanide</title>
            <description>2X 300 mg controlled release tablet twice daily with food for five days</description>
          </group>
        </group_list>
        <measure>
          <title>Time Loss From Work</title>
          <description>Time loss from work</description>
          <population>Analysis conducted on 241 patients with laboratory confirmed influenza excluding those who are unemployed</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="2.17" upper_limit="3.11"/>
                    <measurement group_id="O2" value="3.0" lower_limit="2.43" upper_limit="3.49"/>
                    <measurement group_id="O3" value="3.3" lower_limit="2.75" upper_limit="3.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complications of Influenza</title>
        <description>Proportion of patients with a complication of influenza during the course of the study</description>
        <time_frame>28 days</time_frame>
        <population>All patients who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>300 mg nitazoxanide twice daily with food for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo tablet twice daily with food for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Nitazoxanide</title>
            <description>2X 300 mg controlled release tablet twice daily with food for five days</description>
          </group>
        </group_list>
        <measure>
          <title>Complications of Influenza</title>
          <description>Proportion of patients with a complication of influenza during the course of the study</description>
          <population>All patients who received at least one dose of study medication</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bronchitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinusitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pleurisy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Otitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Influenza Antibody Response Titer Change: Influenza A 2009 H1N1</title>
        <description>change in influenza antibody titer for Influenza A 2009 H1N1</description>
        <time_frame>28 days</time_frame>
        <population>Member of the intensive virologic follow up group with laboratory confirmed Influenza A 2009 H1N1</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>300 mg nitazoxanide twice daily with food for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo tablet twice daily with food for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Nitazoxanide</title>
            <description>2X 300 mg controlled release tablet twice daily with food for five days</description>
          </group>
        </group_list>
        <measure>
          <title>Influenza Antibody Response Titer Change: Influenza A 2009 H1N1</title>
          <description>change in influenza antibody titer for Influenza A 2009 H1N1</description>
          <population>Member of the intensive virologic follow up group with laboratory confirmed Influenza A 2009 H1N1</population>
          <units>Fold change in antibody titer</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O3" value="2" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Influenza Antibody Response: Influenza A H3N2</title>
        <description>Change in antibody titer for Influenza A H3N2</description>
        <time_frame>28 days</time_frame>
        <population>Members of the intensive virologic follow up group with laboratory confirmed influenza A H3N2</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>300 mg nitazoxanide twice daily with food for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo tablet twice daily with food for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Nitazoxanide</title>
            <description>2X 300 mg controlled release tablet twice daily with food for five days</description>
          </group>
        </group_list>
        <measure>
          <title>Influenza Antibody Response: Influenza A H3N2</title>
          <description>Change in antibody titer for Influenza A H3N2</description>
          <population>Members of the intensive virologic follow up group with laboratory confirmed influenza A H3N2</population>
          <units>Fold change in antibody titer</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="4" upper_limit="16"/>
                    <measurement group_id="O2" value="16" lower_limit="2" upper_limit="56"/>
                    <measurement group_id="O3" value="16" lower_limit="10" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Influenza Antibody Response: Influenza B</title>
        <description>Change in antibody titer for Influenza B</description>
        <time_frame>28 days</time_frame>
        <population>Members of intensive virologic follow up group with laboratory confirmed Influenza B</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>300 mg nitazoxanide twice daily with food for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo tablet twice daily with food for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Nitazoxanide</title>
            <description>2X 300 mg controlled release tablet twice daily with food for five days</description>
          </group>
        </group_list>
        <measure>
          <title>Influenza Antibody Response: Influenza B</title>
          <description>Change in antibody titer for Influenza B</description>
          <population>Members of intensive virologic follow up group with laboratory confirmed Influenza B</population>
          <units>Fold change in antibody titer</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="1" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Influenza Antibody Response: Seroprotection and Seroconversion for Patients With Influenza A 2009 H1N1</title>
        <description>Proportion of patients seroprotected or seroconverted at day 28</description>
        <time_frame>28 days</time_frame>
        <population>Members of intensive virologic follow up group with laboratory confirmed Influenza A 2009 H1N1</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>300 mg nitazoxanide twice daily with food for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo tablet twice daily with food for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Nitazoxanide</title>
            <description>2X 300 mg controlled release tablet twice daily with food for five days</description>
          </group>
        </group_list>
        <measure>
          <title>Influenza Antibody Response: Seroprotection and Seroconversion for Patients With Influenza A 2009 H1N1</title>
          <description>Proportion of patients seroprotected or seroconverted at day 28</description>
          <population>Members of intensive virologic follow up group with laboratory confirmed Influenza A 2009 H1N1</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroprotected at day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconverted at day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Influenza Antibody Response: Seroprotection and Seroconversion for Patients With Influenza A H3N2</title>
        <description>Proportion of patients seroprotected and seroconverted at day 28</description>
        <time_frame>28 days</time_frame>
        <population>Members of intensive virologic follow up group with laboratory confirmed Influenza A H3N2</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>300 mg nitazoxanide twice daily with food for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo tablet twice daily with food for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Nitazoxanide</title>
            <description>2X 300 mg controlled release tablet twice daily with food for five days</description>
          </group>
        </group_list>
        <measure>
          <title>Influenza Antibody Response: Seroprotection and Seroconversion for Patients With Influenza A H3N2</title>
          <description>Proportion of patients seroprotected and seroconverted at day 28</description>
          <population>Members of intensive virologic follow up group with laboratory confirmed Influenza A H3N2</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroprotected at day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconverted at day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Influenza Antibody Response: Seroprotection and Seroconversion for Influenza B</title>
        <description>Proportion of patients seroprotected and seroconverted at day 28</description>
        <time_frame>28 days</time_frame>
        <population>Members of intensive virologic follow up group with laboratory confirmed Influenza B</population>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>300 mg nitazoxanide twice daily with food for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo tablet twice daily with food for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Nitazoxanide</title>
            <description>2X 300 mg controlled release tablet twice daily with food for five days</description>
          </group>
        </group_list>
        <measure>
          <title>Influenza Antibody Response: Seroprotection and Seroconversion for Influenza B</title>
          <description>Proportion of patients seroprotected and seroconverted at day 28</description>
          <population>Members of intensive virologic follow up group with laboratory confirmed Influenza B</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroprotected at day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconverted at day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nitazoxanide</title>
          <description>300 mg nitazoxanide twice daily with food for 5 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo tablet twice daily with food for 5 days</description>
        </group>
        <group group_id="E3">
          <title>Nitazoxanide</title>
          <description>2X 300 mg controlled release tablet twice daily with food for five days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>moderate pneumonia</sub_title>
                <description>Patient experienced influenza symptoms 18 hours prior to 600mg NTZ enrollment. Patient had Body Mass Index (BMI) 48.5, history of osteoarthritis &amp; hypertension. Tests reveal 2009 H1N1. Investigator noted adverse event was not related to study drug.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>respiratory syncytial virus type A</sub_title>
                <description>Patient presented influenza type symptoms 44 hours prior to enrollment to placebo group. Completed medication &amp; symptoms resolved. Day 17, admitted to hospital with hypertensive emergency. Investigator noted adverse event not related to study drug.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mild Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="201"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="212"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Presentation and/or publication is encouraged provided the Sponsor is notified in advance and given the opportunity to review the manuscript or abstract 30 days prior to its submission for presentation at a scientific meeting or for publication in a scientific journal. The investigators will have complete autonomy regarding the content and wording including the decision of whether or not to publish.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marc Ayers</name_or_title>
      <organization>Romark Laboratories, L.C.</organization>
      <phone>813-282-8544</phone>
      <email>Marc.Ayers@romark.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

